TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22176583

Group type: EXPERIMENTAL
Intervention: Sit-to-stand activity prompted by health care aides (twice daily during care routines)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 22176869

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5mg once daily continuously with 4-week cycle
Number of subjects: 56
Study: 22177085

Group type: EXPERIMENTAL
Intervention: High cereal-fiber diet (HCF, 43 g/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: High-protein diet (HP, 28% of energy-intake, cereal-fiber 14 g/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Moderately high cereal fiber/protein diet (MIX, protein 23% of energy-intake, cereal-fiber 26 g/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control diet (cereal-fiber 14 g/day)
Number of subjects: 69
Study: 22178121

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) and cisplatin (100 mg/m(2)) on days 1, 22, and 43 of radiation (70 Gy) with intensity-modulated radiation therapy over 33 days, followed by bevacizumab (15 mg/kg) and cisplatin (80 mg/m(2)) on days 64, 85, and 106 after radiation, and fluorouracil (1000 mg/m(2) per day) on days 64-67, 85-88, and 106-109 after radiation.
Number of subjects: 46
Study: 22178570

Group type: EXPERIMENTAL
Intervention: Multiplex FBE kindreds
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Nonfamilial EAC cases
Number of subjects: 1145
Study: 22179034

Group type: EXPERIMENTAL
Intervention: CRT implantation
Number of subjects: 2438
Study: 22179536

Group type: EXPERIMENTAL
Intervention: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions via over-the-wire balloon system or fine-cross microcatheter for 30 minutes.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions.
Number of subjects: 20
Study: 22179957

Group type: EXPERIMENTAL
Intervention: CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator)
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: CUN-BAE
Number of subjects: 6510
Study: 22180164

Group type: EXPERIMENTAL
Intervention: R-EPOCH
Number of subjects: 150

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 150
Study: 22180427

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Desferrioxamine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of deferiprone and desferrioxamine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deferiprone-containing regimens
Number of subjects: 32
Study: 22182397

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% dermal patch) after pretreatment with lidocaine 2.5%/prilocaine 2.5% cream
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% dermal patch)
Number of subjects: 24
Study: 22182735

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT)
Number of subjects: 22052

Group type: EXPERIMENTAL
Intervention: Microscopy
Number of subjects: 22052
Study: 22183039

Group type: COMPARATOR
Intervention: Presumptive diagnosis of malaria (control)
Number of subjects: 52116

Group type: EXPERIMENTAL
Intervention: Microscopy
Number of subjects: 52116

Group type: EXPERIMENTAL
Intervention: RDT
Number of subjects: 52116
Study: 22183105

Group type: EXPERIMENTAL
Intervention: MonoMax® suture material
Number of subjects: 150

Group type: COMPARATOR
Intervention: MonoPlus® or PDS® (Control)
Number of subjects: 150
Study: 22183907

Group type: EXPERIMENTAL
Intervention: Intraoperative laryngeal electromyography (LEMG)
Number of subjects: 25
Study: 22184407

Group type: EXPERIMENTAL
Intervention: PEG-ADA treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Untreated murine ADA(-/-) Tregs
Number of subjects: 0
Study: 22185672

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (standard treatment)
Number of subjects: 50
Study: 22185681

Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg acetate methylprednisolone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intra-articular injection of 80 mg acetate methylprednisolone
Number of subjects: 17
Study: 22185733

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Decongestion (0.05% oxymetazoline chloride applied as an aerosol spray)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Decongestion with ENDS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Basal condition
Number of subjects: 32
Study: 22186627

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.5 mg/m2) administered twice a week for 2 consecutive weeks (days 1, 4, 8, and 11) followed by a 10-day rest period.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.5 mg/m2) administered as described above.
Number of subjects: 18
Study: 22188558

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to abdomen
Number of subjects: 72

Group type: COMPARATOR
Intervention: 1.62% testosterone gel applied to abdomen with t-shirt barrier
Number of subjects: 72

Group type: COMPARATOR
Intervention: 1.62% testosterone gel applied to upper arms and shoulders with t-shirt barrier
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to upper arms and shoulders or combination with abdomen without t-shirt barrier
Number of subjects: 72
Study: 22189084

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400mg)
Number of subjects: 0
Study: 22189340

Group type: EXPERIMENTAL
Intervention: 1 g ertapenem
Number of subjects: 23
Study: 22190166

Group type: EXPERIMENTAL
Intervention: Two-tiered trauma team activation protocol
Number of subjects: 1812
Study: 22190606

Group type: COMPARATOR
Intervention: 200 mg of etravirine/12 h (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 400 mg of etravirine/24 h (Intervention)
Number of subjects: 8
Study: 22190676

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: All diets (low-fat, Mediterranean, low-carbohydrate)
Number of subjects: 322
Study: 22192371

Group type: EXPERIMENTAL
Intervention: XIENCE V Everolimus Eluting Coronary Stent System (EECSS)
Number of subjects: 5054
Study: 22192795

Group type: EXPERIMENTAL
Intervention: Summer vacation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Summer effect on BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight-Z and BMI-Z velocities
Number of subjects: 0
Study: 22192966

Group type: EXPERIMENTAL
Intervention: C1 INH-nf, 1,000 U intravenously
Number of subjects: 113
Study: 22197613

Group type: EXPERIMENTAL
Intervention: Vatalanib 1250 mg orally once daily
Number of subjects: 47
Study: 22197618

Group type: EXPERIMENTAL
Intervention: Subcoronary Ross operation
Number of subjects: 203
Study: 22198152

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EX-527 (SIRT1 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-cultured competitor cells)
Number of subjects: 0
Study: 22198310

Group type: EXPERIMENTAL
Intervention: Lymphodepletion induced by chemo-radiotherapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PR1 responses in CML patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PR1 responses in ALL patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: WT1-126 peptide vaccination
Number of subjects: 27
Study: 22198309

Group type: EXPERIMENTAL
Intervention: peginterferon α-2b + imatinib
Number of subjects: 8
Study: 22198412

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg oral daily) plus Bevacizumab (10 mg/kg IV every 2 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lapatinib plus Bevacizumab
Number of subjects: 52
Study: 22198787

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT) for malaria
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Reattendance after negative RDT
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Severe illness outcomes
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Mortality outcomes
Number of subjects: 5670
Study: 22202188

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 1-Hz to the undamaged right hemisphere
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) followed by speech therapy (constraint-induced language therapy)
Number of subjects: 0
Study: 22203761

Group type: EXPERIMENTAL
Intervention: Subcutaneous GM-CSF during cycle 1 and intravenous GM-CSF during cycle 4
Number of subjects: 151

Group type: COMPARATOR
Intervention: Subcutaneous GM-CSF at both cycles
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Anti-GD2 monoclonal antibody and GM-CSF
Number of subjects: 151

Group type: COMPARATOR
Intervention: Second-line cyclophosphamide-based therapy before protocol entry
Number of subjects: 151
Study: 22206353

Group type: EXPERIMENTAL
Intervention: Indacaterol treatment
Number of subjects: 3313
Study: 22206473

Group type: EXPERIMENTAL
Intervention: Endogenously released glucose, insulin, GLP-1, ghrelin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GLP-1 level at 30 min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ghrelin levels
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Change in glucose level at 30 min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin 0-30 min AUC
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ghrelin 0-120 min AUC
Number of subjects: 23
Study: 22206581

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17P) 250 mg in 1 mL castor oil, weekly intramuscular injection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (1 mL castor oil), weekly intramuscular injection
Number of subjects: 12
Study: 22206727

Group type: EXPERIMENTAL
Intervention: IL-8 in inflamed patients (n = 46)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IL-10 in noninflamed patients (n = 54)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aβ1-42/40 in noninflamed patients (n = 54)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amyloid-β levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 100
Study: 22207464

Group type: EXPERIMENTAL
Intervention: Volumetric MRI and MRS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (term infants)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Volumetric MRI
Number of subjects: 24
Study: 22209268

Group type: EXPERIMENTAL
Intervention: ABSORB BVS 1.1 implantation at 6 months follow-up
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ABSORB BVS 1.1 implantation at 12 months follow-up
Number of subjects: 58
Study: 22210086

Group type: EXPERIMENTAL
Intervention: Erlotinib with docetaxel
Number of subjects: 25
Study: 22210091

Group type: EXPERIMENTAL
Intervention: Panitumumab at 6 mg/kg every 14 days (cycle length = 28 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 20
Study: 22211928

Group type: EXPERIMENTAL
Intervention: Tacrolimus QD at 0.1mg/kg/day
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Tacrolimus QD
Number of subjects: 346
Study: 22212516

Group type: EXPERIMENTAL
Intervention: IABP therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IL-6, IL-7, IL-8, IL-10 (inflammatory markers)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 40
Study: 22212857

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22212936

Group type: EXPERIMENTAL
Intervention: Sorafenib administration after curative treatment (resection or ablation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α2a long-term maintenance therapy
Number of subjects: 0
Study: 22213129

Group type: EXPERIMENTAL
Intervention: Effusion
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Prevalent cartilage damage in the same subregion
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Baseline meniscal extrusion
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Prevalent bone marrow lesions
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Prevalent cartilage damage
Number of subjects: 177
Study: 22215271

Group type: EXPERIMENTAL
Intervention: Office-based buprenorphine-naloxone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Office-based buprenorphine-naloxone treatment with 50% price reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Office-based buprenorphine-naloxone treatment with alternative quality-of-life weights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research to reduce quality-of-life uncertainties
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 22216169

Group type: EXPERIMENTAL
Intervention: Cohort 1 (n=2,274) undergoing first-time diagnostic coronary angiography
Number of subjects: 3165

Group type: EXPERIMENTAL
Intervention: Cohort 2 (n=590) with acute myocardial infarction requiring percutaneous revascularization
Number of subjects: 3165

Group type: EXPERIMENTAL
Intervention: Cohort 3 (n=301) with known left main coronary artery disease
Number of subjects: 3165

Group type: EXPERIMENTAL
Intervention: Cohort 1 (n=2,274)
Number of subjects: 3165
Study: 22217562

Group type: EXPERIMENTAL
Intervention: Physical activity (measured by past-year physical activity questionnaire score)
Number of subjects: 464
Study: 22217879

Group type: EXPERIMENTAL
Intervention: Stable blood pressure (no more than a 1-mm Hg change per month)
Number of subjects: 10245

Group type: EXPERIMENTAL
Intervention: Increasing blood pressure (over 1-mm Hg per month)
Number of subjects: 10245

Group type: EXPERIMENTAL
Intervention: Decreasing blood pressure (less than 1-mm Hg per month)
Number of subjects: 10245

Group type: EXPERIMENTAL
Intervention: Use of cardioprotective drugs for 1 month or more
Number of subjects: 10245

Group type: COMPARATOR
Intervention: Not applicable (control group for comparison)
Number of subjects: 10245
Study: 22217965

Group type: EXPERIMENTAL
Intervention: Lifestyle behaviors before IVF cycle
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lifestyle behaviors during ART cycle
Number of subjects: 118
Study: 22218159

Group type: EXPERIMENTAL
Intervention: Television viewing (≥7 h compared with <1 h/d)
Number of subjects: 240819

Group type: EXPERIMENTAL
Intervention: Television viewing (≥7 h/d) among adults reporting high levels of MVPA (>7 h/wk)
Number of subjects: 240819
Study: 22218721

Group type: EXPERIMENTAL
Intervention: Weekly low-dose (25,000 IU) vitamin A
Number of subjects: 62662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62662
Study: 22218909

Group type: EXPERIMENTAL
Intervention: Gemcitabine at 1,000 mg/m(2) and oxaliplatin at 100 mg/m(2) every 2 weeks
Number of subjects: 28
Study: 22219223

Group type: EXPERIMENTAL
Intervention: Polyfunctional, highly differentiated effector CD4(+) T-cell responses targeting antigens of underlying co-infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: T-cell responses to HIV-1 or other underlying infections
Number of subjects: 0
Study: 22221511

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 12
Study: 22221738

Group type: EXPERIMENTAL
Intervention: Condom distribution and peer education intervention in high risk venues
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control community
Number of subjects: 72
Study: 22222076

Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard care (comparator group)
Number of subjects: 78
Study: 22222143

Group type: EXPERIMENTAL
Intervention: Myotonometric measurement of muscle tone, elasticity, and stiffness
Number of subjects: 67
Study: 22222175

Group type: EXPERIMENTAL
Intervention: Bipolar manic patients carrying the Met allele
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bipolar depressed patients with the Met allele
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy homozygous subjects with the Met allele
Number of subjects: 64
Study: 22223235

Group type: EXPERIMENTAL
Intervention: tPA plus Argatroban (100-μg/kg bolus and infusion for 48 hours)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: tPA plus Argatroban
Number of subjects: 65
Study: 22223821

Group type: EXPERIMENTAL
Intervention: rFVIIIFc (recombinant factor VIII Fc fusion protein) at doses of 25 or 65 IU/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: rFVIII (standard factor VIII product)
Number of subjects: 16
Study: 22223838

Group type: EXPERIMENTAL
Intervention: Early sexual debut (15 years or younger)
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: Overall risk factors considered
Number of subjects: 3492
Study: 22225488

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with 1, 3, or 5 fractions for median doses of 18, 27, and 30 Gy respectively.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 93
Study: 22225857

Group type: EXPERIMENTAL
Intervention: 30mg of pioglitazone alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30mg of pioglitazone after 81mg of aspirin
Number of subjects: 40
Study: 22228003

Group type: EXPERIMENTAL
Intervention: Influenza A/H1N1/09 vaccination in children with celiac disease
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (age-/sex-matched)
Number of subjects: 14
Study: 22228076

Group type: EXPERIMENTAL
Intervention: Malawian infants
Number of subjects: 75

Group type: COMPARATOR
Intervention: Finnish infants
Number of subjects: 75
Study: 22228413

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 22228449

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day for 4 weeks followed by 2 weeks of rest
Number of subjects: 31
Study: 22228827

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT) for depression in Parkinson disease, provided for 10 weeks, supplemented with 4 phone-based caregiver educational sessions.
Number of subjects: 21
Study: 22229310

Group type: EXPERIMENTAL
Intervention: NicVAX (nicotine vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-nicotine antibodies
Number of subjects: 0
Study: 22230151

Group type: EXPERIMENTAL
Intervention: Stent thrombosis at coronary bifurcations
Number of subjects: 20
Study: 22231150

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral opioid analgesia (morphine or hydromorphone) via patient-controlled analgesia (PCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous fluids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 0
Study: 22232031

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of cultured autologous bone marrow stromal cells (BMSCs)
Number of subjects: 5
Study: 22232483

Group type: EXPERIMENTAL
Intervention: β-Blocking treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no β-Blocking treatment)
Number of subjects: 0
Study: 22233350

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 203
Study: 22233455

Group type: EXPERIMENTAL
Intervention: Memantine plus Vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 0
Study: 22233617

Group type: EXPERIMENTAL
Intervention: Treatment according to European guidelines on cardiovascular disease prevention
Number of subjects: 811

Group type: COMPARATOR
Intervention: Control group (778 subjects)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 811

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 811
Study: 22233865

Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 15
Study: 22234149

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg: 3159 patients; 10 mg: 160 patients)
Number of subjects: 5239

Group type: COMPARATOR
Intervention: Comparators (placebo: 977 patients; glimepiride 1-4 mg: 781 patients; voglibose 0.6 mg: 162 patients)
Number of subjects: 5239

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 5239

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 5239
Study: 22234282

Group type: EXPERIMENTAL
Intervention: Binge eating (self-reported presence at baseline)
Number of subjects: 180
Study: 22234714

Group type: EXPERIMENTAL
Intervention: Reading rehabilitation program
Number of subjects: 18
Study: 22234716

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) users
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Massage therapy (most preferred CAM option)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Chiropractic care (least preferred CAM option)
Number of subjects: 401

Group type: COMPARATOR
Intervention: CAM users vs nonusers
Number of subjects: 401
Study: 22235096

Group type: EXPERIMENTAL
Intervention: OXi4503 (combretastatin A1 diphosphate, CA1P) administered intravenously at escalating doses from 0.06 to 1.92 mg/m(2), then expanded cohorts to 15.4 mg/m(2) on days 1, 8, and 15 every 28 days.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of OXi4503 was 8.5 mg/m(2), escalation to 14 mg/m(2) was possible with temporary reversible cerebrovascular toxicity.
Number of subjects: 43
Study: 22235243

Group type: EXPERIMENTAL
Intervention: Weekly 135 µg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks
Number of subjects: 58
Study: 22235252

Group type: EXPERIMENTAL
Intervention: Undifferentiated MDD
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Atypical MDD
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Melancholic MDD
Number of subjects: 89

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 89
Study: 22236356

Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 4344

Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 4344

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4344
Study: 22236384

Group type: EXPERIMENTAL
Intervention: Autologous bone-marrow-derived mesenchymal stem cells (1·6×10(6) cells per kg bodyweight, range 1·1-2·0)
Number of subjects: 10